Sees FY25 Cell Engineering revenue $110M-$130M with potential upside from the recent launch of Tools offerings Ginkgo expects Biosecurity revenue in 2025 of at least $50M, representing approximate current contracted backlog and expected program renewal along with key assumption of continued availability of government funding, with potential upside from additional opportunities in the pipeline
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Ginkgo Bioworks reports Q4 EPS ($2.00), consensus ($1.30)
- Ginkgo Bioworks options imply 17.6% move in share price post-earnings
- DNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ginkgo Bioworks integrates Callisto for NGS processes
- Ginkgo Bioworks partners with HaDEA in up to EUR 24M project
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue